Published in Ann Intern Med on July 19, 2011
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol (2014) 3.12
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut (2013) 2.86
Identification of Lynch syndrome among patients with colorectal cancer. JAMA (2012) 2.77
Cost-effectiveness and diagnostic effectiveness analyses of multiple algorithms for the diagnosis of Lynch syndrome. Dig Dis Sci (2014) 2.77
The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genet Med (2014) 1.68
Selective Versus Universal Screening for Lynch Syndrome: A Six-Year Clinical Experience. Dig Dis Sci (2014) 1.50
Comparative effectiveness of screening strategies for Lynch syndrome. J Natl Cancer Inst (2015) 1.47
Issues surrounding the health economic evaluation of genomic technologies. Pharmacogenomics (2013) 1.45
Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol (2013) 1.33
Multilevel research and the challenges of implementing genomic medicine. J Natl Cancer Inst Monogr (2012) 1.21
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer (2013) 1.21
Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis. J Clin Oncol (2015) 1.16
Familial colon cancer syndromes: an update of a rapidly evolving field. Curr Gastroenterol Rep (2012) 1.16
Screening for Lynch syndrome: it is time to shift the focus. Dig Dis Sci (2015) 1.10
Economic evaluation of genetic screening for Lynch syndrome in Germany. Genet Med (2015) 1.10
Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. J Clin Oncol (2016) 1.06
Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility. Genet Med (2013) 1.04
Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry. Fam Cancer (2013) 1.03
Familial colorectal cancer, beyond Lynch syndrome. Clin Gastroenterol Hepatol (2013) 1.03
Comparing universal Lynch syndrome tumor-screening programs to evaluate associations between implementation strategies and patient follow-through. Genet Med (2014) 1.00
Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol (2015) 0.96
Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer. Genet Med (2013) 0.95
History, genetics, and strategies for cancer prevention in Lynch syndrome. Clin Gastroenterol Hepatol (2013) 0.95
Impact of age cutoffs on a lynch syndrome screening program. J Oncol Pract (2012) 0.90
Evolving approach and clinical significance of detecting DNA mismatch repair deficiency in colorectal carcinoma. Semin Diagn Pathol (2015) 0.89
Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review. Fam Cancer (2014) 0.87
Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome. J Oncol Pract (2012) 0.87
Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas. Mod Pathol (2013) 0.86
Implementation of routine screening for Lynch syndrome in university and safety-net health system settings: successes and challenges. Genet Med (2013) 0.86
Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome. Cancer (2012) 0.86
Evaluating the utilization of educational materials in communicating about Lynch syndrome to at-risk relatives. Fam Cancer (2014) 0.85
Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy. BMC Cancer (2015) 0.85
Deficient mismatch repair: Read all about it (Review). Int J Oncol (2015) 0.84
Biomarkers, bundled payments, and colorectal cancer care. Genes Cancer (2012) 0.84
Prediction models in Lynch syndrome. Fam Cancer (2013) 0.84
The genetic basis of Lynch syndrome and its implications for clinical practice and risk management. Appl Clin Genet (2014) 0.84
Who should have genetic testing for the Lynch syndrome? Ann Intern Med (2011) 0.83
Reflex testing for Lynch syndrome: if we build it, will they come? Lessons learned from the uptake of clinical genetics services by individuals with newly diagnosed colorectal cancer (CRC). Fam Cancer (2014) 0.82
Stakeholder perspectives on implementing a universal Lynch syndrome screening program: a qualitative study of early barriers and facilitators. Genet Med (2015) 0.82
Next generation sequencing and a new era of medicine. Gut (2012) 0.82
When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives. Healthcare (Basel) (2015) 0.81
Clinical characterization and mutation spectrum in Caribbean Hispanic families with Lynch syndrome. Fam Cancer (2015) 0.81
Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing. Gynecol Oncol (2015) 0.81
Comparative‑high resolution melting: a novel method of simultaneous screening for small mutations and copy number variations. Hum Genet (2014) 0.80
Colorectal cancer survivors' interest in genetic testing for hereditary cancer: implications for universal tumor screening. Genet Test Mol Biomarkers (2012) 0.80
Is the ``$1000 Genome'' really $1000? Understanding the full benefits and costs of genomic sequencing. Technol Health Care (2015) 0.80
Genetic testing strategies in newly diagnosed endometrial cancer patients aimed at reducing morbidity or mortality from lynch syndrome in the index case or her relatives. PLoS Curr (2013) 0.80
Universal tumor screening for Lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. Cancer (2015) 0.80
Genetic testing for lynch syndrome, an inherited cancer of the bowel, endometrium, and ovary. Rev Obstet Gynecol (2012) 0.79
Identifying persons with Lynch syndrome: why and how? Dig Dis Sci (2014) 0.79
A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. BMC Cancer (2015) 0.79
Testing women with endometrial cancer for lynch syndrome: should we test all? J Adv Pract Oncol (2013) 0.78
Is breast cancer a part of Lynch syndrome? Breast Cancer Res (2012) 0.78
Communication and technology in genetic counseling for familial cancer. Clin Genet (2013) 0.78
Detecting Germline PTEN Mutations Among At-Risk Patients With Cancer: An Age- and Sex-Specific Cost-Effectiveness Analysis. J Clin Oncol (2015) 0.78
A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers. Appl Health Econ Health Policy (2016) 0.78
Biomarker-directed Targeted Therapy in Colorectal Cancer. J Dig Cancer Rep (2015) 0.78
Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Genet Med (2015) 0.77
Universal Screening of Colorectal Cancers for Lynch Syndrome: Challenges and Opportunities. Dig Dis Sci (2015) 0.77
Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age. Genet Med (2016) 0.76
Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol (2012) 0.76
Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen. Clin Colon Rectal Surg (2016) 0.75
Epidemiology matters: peering inside the "black box" in economic evaluations of genetic testing. Genet Med (2016) 0.75
Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan. PLoS One (2016) 0.75
Chemoprevention of endometrial cancer in Lynch syndrome: a step forward. Cancer Prev Res (Phila) (2013) 0.75
Hereditary colorectal cancer registries in Canada: report from the Colorectal Cancer Association of Canada consensus meeting; Montreal, Quebec; October 28, 2011. Curr Oncol (2013) 0.75
Applying public health screening criteria: how does universal newborn screening compare to universal tumor screening for Lynch syndrome in adults with colorectal cancer? J Genet Couns (2014) 0.75
Tumour testing to identify Lynch syndrome in two Australian colorectal cancer cohorts. J Gastroenterol Hepatol (2016) 0.75
Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations. Genet Med (2016) 0.75
A Novel WRN Frameshift Mutation Identified by Multiplex Genetic Testing in a Family with Multiple Cases of Cancer. PLoS One (2015) 0.75
Recent advances in understanding Lynch syndrome. F1000Res (2016) 0.75
Role of the clinical pathology laboratory in the evaluation of endometrial carcinomas for Lynch syndrome. Semin Diagn Pathol (2014) 0.75
Successful implementation of Lynch syndrome screening in a safety net institution. J Community Genet (2016) 0.75
Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample. Med Decis Making (2015) 0.75
Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer. Int J Environ Res Public Health (2016) 0.75
Screening for Cancer Genetic Syndromes With a Simple Risk-Assessment Tool in a Community-Based Open-Access Colonoscopy Practice. Am J Gastroenterol (2016) 0.75
Can a gastrointestinal pathologist identify microsatellite instability in colorectal cancer with reproducibility and a high degree of specificity? Fam Cancer (2012) 0.75
Performance of Lynch syndrome predictive models in quantifying the likelihood of germline mutations in patients with abnormal MLH1 immunoexpression. Fam Cancer (2017) 0.75
Hereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management. Am J Gastroenterol (2017) 0.75
Approach to Lynch Syndrome for the Gastroenterologist. Dig Dis Sci (2016) 0.75
A Systematic Review on the Existing Screening Pathways for Lynch Syndrome Identification. Front Public Health (2017) 0.75
Lynch syndrome: the patients' perspective. Fam Cancer (2013) 0.75
Evolution of cancer risk assessment and counseling related to psychological, financial and legal implications. Fam Cancer (2016) 0.75
Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2008) 16.82
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA (1996) 14.23
The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell (1993) 13.54
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology (1999) 11.94
Hereditary colorectal cancer. N Engl J Med (2003) 11.86
A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med (1992) 10.70
Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med (2005) 9.39
Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med (2000) 8.68
Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA (1996) 8.52
Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med (1998) 8.47
Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology (2000) 8.41
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol (2006) 7.43
Microsatellite instability in colorectal cancer. Gastroenterology (2010) 7.39
Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med (2008) 7.26
Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer (1999) 6.73
Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med (2002) 5.76
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med (2006) 5.70
Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol (2008) 5.47
Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med (1993) 5.00
Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med (2006) 4.95
Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA (2006) 4.87
Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial. Lancet (2004) 4.65
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
The "duty to warn" a patient's family members about hereditary disease risks. JAMA (2004) 4.13
Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA (2005) 3.99
Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol (2000) 3.98
Short term benefits for laparoscopic colorectal resection. Cochrane Database Syst Rev (2005) 3.95
Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology (2008) 3.71
Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst (2003) 3.71
EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med (2009) 3.57
A prospective, randomized trial comparing laparoscopic versus conventional techniques in colorectal cancer surgery: a preliminary report. J Am Coll Surg (1998) 3.52
Endoscopic perforation of the colon: lessons from a 10-year study. Am J Gastroenterol (2000) 3.52
Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet (1997) 3.41
It is time to get serious about diagnosing Lynch syndrome (hereditary nonpolyposis colorectal cancer with defective DNA mismatch repair) in the general population. Gastroenterology (2005) 3.30
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86
The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med (2010) 2.81
Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology (2005) 2.80
Risk of perforation from a colonoscopy in adults: a large population-based study. Gastrointest Endosc (2009) 2.78
Vital signs: colorectal cancer screening among adults aged 50-75 years - United States, 2008. MMWR Morb Mortal Wkly Rep (2010) 2.75
The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology (2001) 2.68
Laparoscopic versus open colorectal surgery: a randomized trial on short-term outcome. Ann Surg (2002) 2.50
Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand. Gastroenterology (2005) 2.50
Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn (2008) 2.30
Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. Am J Hum Genet (2000) 2.29
Process and outcome in communication of genetic information within families: a systematic review. Eur J Hum Genet (2007) 2.15
Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol (2009) 1.92
One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology (2010) 1.91
The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology (2010) 1.88
Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Colorectal Dis (2009) 1.75
The impact of predictive genetic testing for hereditary nonpolyposis colorectal cancer: three years after testing. Genet Med (2007) 1.74
Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer (2007) 1.67
Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet (2006) 1.59
How families communicate about HNPCC genetic testing: findings from a qualitative study. Am J Med Genet C Semin Med Genet (2003) 1.54
Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med (2001) 1.50
Microsatellite instability in colorectal cancer. Br J Surg (2006) 1.46
Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications. Evid Rep Technol Assess (Full Rep) (2007) 1.42
Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol (2005) 1.41
Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst (2009) 1.40
Cost effectiveness of a new strategy to identify HNPCC patients. Gut (2005) 1.38
Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam Cancer (2009) 1.38
Medical Geneticists' duty to warn at-risk relatives for genetic disease. Am J Med Genet A (2003) 1.36
Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin (2006) 1.29
Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. J Med Genet (2008) 1.28
Structure and function of the components of the human DNA mismatch repair system. Int J Cancer (2006) 1.28
Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer (2002) 1.23
An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. Genet Med (2003) 1.18
Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol (2008) 1.17
Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer. J Natl Compr Canc Netw (2010) 1.16
Informing one's family about genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a retrospective exploratory study. Fam Cancer (2005) 1.15
Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res (2010) 1.13
Perceptions of cancer risks and predictors of colon and endometrial cancer screening in women undergoing genetic testing for Lynch syndrome. J Clin Oncol (2008) 1.11
Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? Gynecol Oncol (2008) 1.09
Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. Eur J Cancer (1995) 1.04
New developments in Lynch syndrome (hereditary nonpolyposis colorectal cancer) and mismatch repair gene testing. Gastroenterology (2006) 1.04
Counterpoint: implementing population genetic screening for Lynch Syndrome among newly diagnosed colorectal cancer patients--will the ends justify the means? J Natl Compr Canc Netw (2010) 1.01
Duty to warn at-risk relatives for genetic disease: genetic counselors' clinical experience. Am J Med Genet C Semin Med Genet (2003) 0.99
Direct contact in inviting high-risk members of hereditary colon cancer families to genetic counselling and DNA testing. J Med Genet (2007) 0.97
Cost-effectiveness analysis of annual screening strategies for endometrial cancer. Am J Obstet Gynecol (2009) 0.96
To screen or not to screen for Lynch syndrome. J Natl Cancer Inst (2010) 0.91
Colon cancer screening practices and disclosure after receipt of positive or inconclusive genetic test results for hereditary nonpolyposis colorectal cancer. Cancer (2009) 0.90
Psychologic distress after disclosure of genetic test results regarding hereditary nonpolyposis colorectal carcinoma. Cancer (2004) 0.89
Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome. Fam Cancer (2009) 0.89
Mutation prediction models in Lynch syndrome: evaluation in a clinical genetic setting. J Med Genet (2009) 0.87
A population based cohort study of patients with multiple colon and endometrial cancer: correlation of microsatellite instability (MSI) status, age at diagnosis and cancer risk. Int J Cancer (2001) 0.86
The management of families affected by hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer (2007) 0.82
Awareness of gynecologic surveillance in women from hereditary non-polyposis colorectal cancer families. Fam Cancer (2006) 0.82
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Risk and the pregnant body. Hastings Cent Rep (2009) 4.63
Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology (2004) 4.03
Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst (2013) 4.03
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA (2007) 3.62
Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med (2005) 3.55
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol (2014) 3.07
Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. Arch Intern Med (2011) 3.00
Cost utility of prenatal diagnosis and the risk-based threshold. Lancet (2004) 3.00
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology (2006) 2.63
Cutaneous manifestations of gastrointestinal disease: part I. J Am Acad Dermatol (2013) 2.58
Lynch syndrome: form, function, proteins, and basketball. Gastroenterology (2005) 2.57
Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst (2009) 2.57
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut (2012) 2.40
Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol (2013) 2.38
Effect of managed care insurance on the use of preventive care for specific ethnic groups in the United States. Med Care (2002) 2.34
Predicting the risk of perioperative transfusion for patients undergoing elective hepatectomy. Ann Surg (2009) 2.27
Variation in access to health care for different racial/ethnic groups by the racial/ethnic composition of an individual's county of residence. Med Care (2004) 2.25
Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res (2003) 2.24
Risks, values, and decision making surrounding pregnancy. Obstet Gynecol (2007) 2.11
Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res (2004) 2.10
Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer (2003) 2.07
Exploring utilities and outcomes with infliximab therapy. Clin Gastroenterol Hepatol (2006) 2.04
Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A (2009) 2.02
Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology (2008) 1.97
Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res (2010) 1.88
Measuring patient preferences for colorectal cancer screening using a choice-format survey. Value Health (2007) 1.86
Epigenetic and genetic alterations in Netrin-1 receptors UNC5C and DCC in human colon cancer. Gastroenterology (2007) 1.82
Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res (2008) 1.81
Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev (2010) 1.74
Clinical uses of microsatellite instability testing in colorectal cancer: an ongoing challenge. J Clin Oncol (2007) 1.73
5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology (2010) 1.71
Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol (2002) 1.71
APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol Ther (2004) 1.71
Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes (2014) 1.65
Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila) (2012) 1.65
Penile implant utilization following treatment for prostate cancer: analysis of the SEER-Medicare database. J Sex Med (2011) 1.64
Epigenetics of colorectal cancer. Gastroenterology (2012) 1.60
Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet (2006) 1.59
Mode of delivery: toward responsible inclusion of patient preferences. Obstet Gynecol (2008) 1.57
Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther (2004) 1.57
Impact of labor induction, gestational age, and maternal age on cesarean delivery rates. Obstet Gynecol (2003) 1.57
The association of race, socioeconomic status, and health insurance status with the prevalence of overweight among children and adolescents. Am J Public Health (2003) 1.53
Hysterectomy versus expanded medical treatment for abnormal uterine bleeding: clinical outcomes in the medicine or surgery trial. Obstet Gynecol (2004) 1.52
Recruitment strategies for minority participation: challenges and cost lessons from the POWER interview. Ethn Dis (2005) 1.52
Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol (2005) 1.50
Selective Versus Universal Screening for Lynch Syndrome: A Six-Year Clinical Experience. Dig Dis Sci (2014) 1.50
Day-to-Day Impact of Vaginal Aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women. Menopause (2015) 1.47
Achieving optimal outcomes after radical prostatectomy. J Clin Oncol (2005) 1.46
Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg (2014) 1.46
Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology (2010) 1.46
Decrease in urinary incontinence management costs in women enrolled in a clinical trial of weight loss to treat urinary incontinence. Obstet Gynecol (2012) 1.45
A community-based study of acne-related health preferences in adolescents. Arch Dermatol (2008) 1.44
Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology (2008) 1.43
Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer (2005) 1.43
Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J Biol Chem (2003) 1.42
Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer (2005) 1.42
A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res (2003) 1.41
Association of JC virus T-antigen expression with the methylator phenotype in sporadic colorectal cancers. Gastroenterology (2006) 1.38
Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut (2013) 1.37
Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer (2011) 1.37
Microsatellite instability and suppressed DNA repair enzyme expression in rheumatoid arthritis. J Immunol (2003) 1.32
Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer (2002) 1.32
Racial and ethnic disparities in benign gynecologic conditions and associated surgeries. Am J Obstet Gynecol (2010) 1.32
Rates and predictors of colorectal cancer screening. Prev Chronic Dis (2006) 1.31
High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol Ther (2007) 1.30
Fragmentation of care for frequently hospitalized urban residents. Med Care (2006) 1.29
The effect of area HMO market share on cancer screening. Health Serv Res (2004) 1.29
Real-time optical biopsy of colon polyps with narrow band imaging in community practice does not yet meet key thresholds for clinical decisions. Gastroenterology (2012) 1.28
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One (2013) 1.28
Structure and function of the components of the human DNA mismatch repair system. Int J Cancer (2006) 1.28
Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci U S A (2003) 1.27
How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. Health Econ (2009) 1.27
Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin Cancer Res (2011) 1.27
Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer (2008) 1.27
Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans. Int J Cancer (2005) 1.26
The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One (2012) 1.26
An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers. PLoS One (2010) 1.26
Who should be sent for genetic testing in hereditary colorectal cancer syndromes? J Clin Oncol (2007) 1.26
Induction of chromosomal instability in colonic cells by the human polyomavirus JC virus. Cancer Res (2003) 1.25
A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS One (2012) 1.24
Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers. Oncogene (2002) 1.22
How the new medicare drug benefit could affect vulnerable populations. Health Aff (Millwood) (2006) 1.21
Frequent loss of hMLH1 by promoter hypermethylation leads to microsatellite instability in adenomatous polyps of patients with a single first-degree member affected by colon cancer. Cancer Res (2003) 1.20
Sharing genetic test results in Lynch syndrome: communication with close and distant relatives. Clin Gastroenterol Hepatol (2008) 1.20
Microsatellite instability at tetranucleotide repeats in sporadic colorectal cancer in Japan. Oncol Rep (2010) 1.19
Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer (2004) 1.18
Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. Clin Cancer Res (2006) 1.18
Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells. Int J Cancer (2011) 1.16
How does cost matter in health-care discrete-choice experiments? Health Econ (2011) 1.15
An experiment on simplifying conjoint analysis designs for measuring preferences. Health Econ (2003) 1.14
Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers. Cancer Res (2010) 1.14
Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract (2010) 1.14
MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J Biol Chem (2011) 1.13
Indoor environmental exposures and exacerbation of asthma: an update to the 2000 review by the Institute of Medicine. Environ Health Perspect (2014) 1.13
Oncogenic T-antigen of JC virus is present frequently in human gastric cancers. Cancer (2006) 1.12
Sexual function and aging in racially and ethnically diverse women. J Am Geriatr Soc (2009) 1.11
Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. Oncotarget (2011) 1.11